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Due to the limited intrinsic healing ability of mature cartilage tissue, stem cell 
therapies offer the potential to restore cartilage lost due to trauma or arthritis. 
Mesenchymal stem cells (MSCs) are a promising cell source due to their ability to 
differentiate into various adult tissues under specific biochemical and physical cues. 
Current MSC chondrogenic differentiation strategies employ large pellets, however, we 
have previously developed a high-throughput technique to form small MSC aggregates 
(500-1,000 cells) that may reduce diffusion barriers while maintaining a multicellular 
structure that is analogous to cartilaginous condensations. The objective of this study was 
to examine the effects on chondrogenesis of incorporating chondroitin sulfate 
methacrylate (CSMA) microparticles (MPs) within these small MSC spheroids when 
cultured in the presence of transforming growth factor-β1 (TGF-β1) over 21 days.  
Spheroids +MP induced earlier increases in collagen II and aggrecan gene expression 
(chondrogenic markers) than spheroids -MP, although no large differences in 
immunostaining for these matrix molecules were observed by day 21. Collagen I and X 
was also detected in the ECM of all spheroids by immunostaining. Interestingly, 
histology revealed that CSMA MPs clustered together near the center of the MSC 
spheroids and induced circumferential alignment of cells and ECM around the material 
core. Because chondrogenesis was not hindered by the presence of CSMA MPs, this 
study demonstrates the utility of this culture system to further examine the effects of 
matrix molecules on MSC phenotype, as well as potentially direct differentiation in a 








Cartilage Disease  
In 2005, approximately 27 million adults in the U.S. exhibited clinical 
osteoarthritis (OA) symptoms [1]. It has also been predicted that 1 in 2 Americans will be 
affected by OA in at least one knee during their lifetime [2]. Osteoarthritis is a disease 
that is characterized by the degeneration of articular cartilage. Often, physical trauma 
changes the distribution of load across the articulating surface of the joint, which leads to 
an abnormal tissue remodeling response [3, 4]. Irregularities on the cartilage surface first 
develop due to the altered joint mechanics and stability [3]. However, there is little 
intrinsic repair capacity in cartilage due to variety of reasons, including a lack of 
progenitor cell source and low proliferative and healing ability of resident chondrocytes 
[5]. In response to the altered mechanical force in the joint, chondrocytes that are 
normally in a resting state become proliferative and increase production of matrix-
degrading enzymes, such as metalloproteinases [6], aggrecanses [7], and cathepsins [8]. 
Inflammation can also occur during the early onset of OA due to the initial trauma, in 
which mononuclear cells infiltrate and secrete inflammatory cytokines like interleukin 1β 
and tumor necrosis factor α that drive the catabolic activities in the joint by inducing 
more inflammatory factors (inducible nitric oxide synthase, oncostatin M …etc). [7, 9]. 
The fibrillar network of aggrecan is first degraded by a disintegrin and metalloproteinase 
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with thrombospondin motifs (ADAMTS) followed by cleavage of the collagen II by 
matrix metalloproteinase-13 (MMP-13) and other proteases [3, 4, 8]. The loss of the 
extracellular matrix (ECM) network results in large lesions in the tissue accompanied by 
increased swelling of the cartilage and thickening of the subchondral bone [4], which 
leads to decreased mechanical loading and gliding capacity that are evident in the limited 
joint mobility and increased pain in the patient [10]. 
Cartilage Composition  
Hyaline cartilage is a connective tissue that lines the surface of synovial joints 
such as the knee, allowing articulating motion.  It is a largely avascular and aneural tissue 
with low oxygen tension [11, 12]. The resident cell type in the cartilage is chondrocytes, 
which possess a mature rounded phenotype with a lack of proliferative activity [11] and 
are embedded within a highly organized ECM of collagen, proteoglycans, and 
noncollagenous molecules [13]. The macrofibrillar framework is composed mainly of 
collagen type II, which contributes to the stiffness of the tissue [14], with little collagen I 
and X [15]. Proteoglycans form a sub-lattice structure that fills the interfibrillar space and 
connects to the collagen fibrils, conferring high compressive properties of cartilage [12]. 
Articular cartilage consists of 70-80% water due to the large amounts of proteoglycans 
and 50-90% collagen by dry weight [11]. Comparatively, chondrocytes constitute only a 
small portion of the total tissue volume at 2-5% [12, 15], making cartilage an ECM-rich 
tissue.  
Proteoglycans are composed of glycosaminoglycan (GAG) branches that are 
covalently attached to a core protein. Several classes of proteoglycan are found in the 
cartilage (aggrecan, decorin, biglycan, perlecan and fibromodulin) that differ in the 
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number and type of GAG branches, such as chondroitin sulfate (CS), dermatan sulfate, 
and keratan sulfate [16]. The GAGs enable the proteoglycan to promote collagen fibril 
formation [17] and regulate cell function via interactions with proteins and growth factors 
[18].  In particular, CS is the main GAG constituent of aggrecan, the most abundant 
proteoglycan in the articular cartilage [11, 12]. It is composed of repeating disaccharide 
units glucuronic acid and N-acetyl-galactosamine (GalNAc) with sulfation on  carbon 6 
of GalNAc being the most common in mature cartilage [19]. The highly sulfated CS 
chains impart a high anionic charge to aggrecan, allowing it to interact with ions to 
facilitate the diffusion of water into the cartilage [15], which is the basis for the high 
compressive strength of cartilage [11, 12]. The swelling of the tissue is counteracted by 
the tension from the collagenous network, resulting in the maintenance of osmostic 
pressure within the cartilage during normal mechanical loading of the joint [11, 15].  
Cartilage Development  
The development of cartilage for limb skeletogenesis begins in the embryo as 
mesenchymal cells are recruited from the lateral plate medosderm and aggregate to form 
a skeletal blastema [20]. Within the limb field, chondrogenically-committed 
mesenchymal cells condense due to cell-cell and cell-matrix interactions promoted by the 
expression of cell adhesion molecules (N-cadherin and neural cell adhesion molecules 1 
(NCAM1)) and ECM protein (fibronectin) [21-23]. The activation of several signaling 
pathways also occurs during cartilaginous condensation. Wnt-mediated expression of 
fibroblast growth factor (FGF) and Sonic hedgehog are essential during early limb 
patterning for the regulation of cell proliferation within the condensation [24].  Bone 
morphogenetic protein (BMP) signaling is also required for the formation of cartilaginous 
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condensation and the subsequent differentiation of mesenchymal progenitor cells into 
chondrocytes [25] by regulating expression of master transcription factor (Sex 
Determining Region Y)-Box 9 (SOX9) early in the condensation process to for the 
deposition of collagen II and aggrecan later during chondrogenesis [24, 26, 27]. In 
forming articular cartilage, the chondroprogenitor cells differentiate into resting cells and 
produce aggregan-rich ECM by signaling via integrins (α1, α10, β1)  and collagen 
receptor discoidin domain-containing receptor 2 [26]. Differentiation into chondrocytes is 
followed by proliferation, terminal differentiation, hypertrophy and apoptosis in order to 
form bone by the process of endochondral ossification [28]. 
Although many mechanisms still need to be elucidated, proteoglycans are 
essential in regulating chondrogenesis during embryonic development. Aggrecan has 
been shown to facilitate collagen fibrillogenesis and maintain the collagenous network 
during the development of cartilaginous tissues [29]. The retention of pericellular matrix 
also depends on the interaction of aggrecan-hyaluronan (HA) aggregates with the CD44 
receptors expressed on chondrocyte surface [17]. The loss of aggrecan from the 
developing growth plate has been shown to result in impaired Indian hedgehog homolog, 
FGF, BMP signaling during chondrogenesis [30]. Together, these evidence suggests that 
aggrecan plays an important role in the presentation and regulation of growth factors to 
the maturing mesenchymal cells. Versican, another large CS proteoglycan, is highly 
synthesized by mesenchymal cells in the limb bud to facilitate the cellular condensation 
process by interacting with ECM molecules, fibronectin and collagen I [31], as well as 
growth factors such as transforming growth factor-β 1 (TGF-β1) [32]. Modulation of CS 
proteoglycan expression (i.e. decreased versican and increased aggrecan expression with 
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chondrocyte differentiation) helps maintain the mature chondrogenic phenotype [30]. 
Overall, CS proteoglycans are essential in mediating the process of chondrocyte 
differentiation in the cellular condensations during development.  
In Vitro Chondrogenic Differentiation  
Due to the inefficiency of current therapies to produce load bearing, hyaline-like 
cartilage [5, 13], tissue engineering strategies have been applied to improve the cartilage 
regeneration process. The use of chondrocytes in scaffolds for regenerating cartilage has 
been investigated previously [33-36]. However, the low number of chondrocytes 
available for harvest and associated risk for autologous donor site morbidity are serious 
challenges to their widespread clinical use [37]. In addition, the expansion of 
chondrocytes in vitro prior to scaffold seeding and implantation results in de-
differentiation characterized by changes in gene expression (collagen I, II, and aggrecan) 
as early as the first passage [38]. As a result, chondrocyte-based constructs often produce 
low amounts of collagen, leading to reduced tensile properties relative to healthy 
cartilage [13] and a ratio of chondrocytes, GAG and collagen content that does not 
resemble that of mature cartilage. 
An alternative source of cells is MSCs, which are multipotent with the capacity to 
differentiate into various adult tissues including cartilage under specific physical and 
biochemical stimuli. Chondrogenic differentiation of MSCs from a variety of tissue 
sources, such as adipose tissue and umbilical cord, has been attempted, but bone marrow-
derived MSCs have been shown to exhibit higher chondrogenic potential  [39, 40] and 
was chosen for this study. In order to direct chondrogenesis, material selection for the 
scaffold is also important due to the effects of its physical (i.e. porosity, topography, 
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microstructure...etc) and mechanical properties on stem cell fate [37, 41-43] and will be 
discussed in later sections in more details. Soluble biochemical cues have also been 
identified to promote chondrogenic differentiation of MSCs with TGF-β1, 2, 3 being the 
most common and effective in promoting GAG production and collagen II gene 
expression [44, 45]. Other growth factors, such as BMe-2 and 6 or insulin-like growth 
factor-1, further enhance the effects of TGF-β [46, 47]. The addition of dexamethasone 
with TGF-β also induced more homogeneous deposition of collagen II in MSCs [45, 48]. 
Additionally, scaffold-free high density pellet culture has been widely used to simulate 
the N-cadherin and NCAM1-mediated cell-cell interaction present in cartilaginous 
condensations [22, 24, 49-51]. However, challenges arise with the use of MSCs due to 
the complexity of chondrogenesis in regards to the synchronization of signaling cascades 
and regulatory networks, the crosstalk between genes and effector molecules, and the 
precise pattern of spatial and temporal control that are difficult to mimic in vitro [10, 24, 
27]. In addition, MSCs are found to undergo terminal differentiation similar to 
chondrocytes during endochondral ossification, producing collagen type I and and X, 
alkaline phosphatase, other hypertrophic markers as well as mineralizations in many 
cases [52-54]. Due to the challenge in inducing and maintaining long-term chondrogenic 
phenotype in MSCs, modifications to standard culture conditions are being explored.  
Hypoxic Culture       
In attempt to reduce MSC hypertrophy found in standard differentiation 
conditions, low oxygen tension ranging from 1 to 5% O2 [55-58] have been recapitulated 
in vitro as the cartilaginous condensations present during embryonic limb development 
has been shown to be avascular [59, 60]. Hypoxia has also been shown to prevent 
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chondrocyte proliferation while promoting matrix accumulation [61], by mediating the 
expression of transcription factor hypoxia-inducible factor 1α (HIF-1α), which can 
decrease osteogenic runt-related transcription factor 2 (RUNX2) gene expression and its 
DNA binding activity in human MSCs [55] as well as other cell types including human 
osteoblast-like cells [62] and mouse mesenchymal cells [63]. Additionally, HIF-1α has 
the ability to directly bind to the SOX9 promoter under hypoxia, thus increasing 
chondrogenic gene expression (collagen II and aggrecan) in MSCs and limb bud 
mesenchymal cells [55, 64-67].         
 Hypoxic culture has been shown to both reduce and delay hypertrophic collagen 
X expression while promoting chondrogenic gene markers in MSCs [55, 57, 58]. Sheehy 
et al. reported increased collagen II production with lowered collagen type X, Alizarin 
Red staining and alkaline phosphatase activity in porcine MSC pellets cultured under 5% 
O2 [58]. Human MSCs encapsulated in alginate beads and cultured under 5% O2 without 
the addition of growth factors (i.e. TGF-β) also demonstrated higher increase in collagen 
II and aggrecan, SOX5, 6 and 9 mRNA expression and reduced collagen X, alkaline 
phosphatase and RUNX2 gene expression [55]. In another study, hMSC pellets in 5% O2 
hypoxia were stimulated with either chondrogenic (TGF-β2) or hypertrophic (β-
glycerophophate) medium [57]. Although collagen X protein production was detected in 
all pellets, the progression of hypertrophy appeared to be delayed in low oxygen tension 
as evidenced by the increased gene expression of late hypertrophic markers (osteopontin 
and osteocalcin) under normoxic conditions [57].     
 Despite the ability of some hypoxic culture to suppress hypertrophic expression in 
encapsulated MSCs or pellets [55, 57, 58], others have still reported increase in collagen 
8 
 
X levels [68, 69]. In one study, micropellets of hMSCs were cultured under 2% O2 for 
chondrogenesis with traditional pellets as controls [70]. Increases in aggrecan and 
collagen II gene expression detected in hypoxic micropellets were even higher than that 
in hypoxic pellets, suggesting that aggregate size may play a role in hypoxia-mediated 
chondrogenesis. Although higher and more uniform GAG and collagen II staining was 
also detected in hypoxic micropellets, collagen I and X mRNA expression was markedly 
increased along with osteocalcin [70]. Similarly, ovine MSCs expanded under low 
oxygen tension (5% O2) prior to forming pellets demonstrated increased collagen II and 
aggrecan gene and protein expression along with enhanced GAG deposition [68]. 
However, higher collagen X gene expression was still detected at day 7 in the pellets 
under hypoxia.           
 Although the review here focused primarily on bone marrow-derived 
mesenchymal stem cells, the cell type, species and tissue source may affect the extent of 
hypoxia in reducing hypertrophy [67, 69] as well as differences in the range (% O2) and 
duration of hypoxia. Even the maintenance of low oxygen tension during media changes 
[57] may be critical in preserving the effectiveness of hypoxic culture. Although 
hypertrophic markers may still be expressed under some hypoxic culture, the beneficial 
effect of hypoxia on increasing chondrogenic gene expression in MSCs has been 
consistently reported.        
Three Dimensional Spheroid Culture        
 Culturing cells in a spheroid format has been used to better recapitulate the cell-
cell contact and native structure of both mature and developing tissue [48, 71, 72]. 
Although cells are typically expanded in monolayer, two dimensional culture often leads 
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to decreased tissue-specific or therapeutic properties [73, 74] due to the ability of 
substrate to stimulate cellular differentiation via its physical or mechanical properties 
[42]. As a result, scaffold-free three dimensional culture has been widely explored in 
order to circumvent these issues. Specifically, spheroid culture is distinguished from 
larger aggregates or pellets in that they are typically 100 to 500μm in size, thus reducing 
the diffusional limitations and necrotic core that may accompany pellets greater than 
500μm [73].          
 Spheroids have been formed with a variety of cell types, such as cancer cells [75-
77], hepatocytes [78, 79], and stem cells [71, 79, 80] to study cellular behavior in tumor 
models, hepatic systems, high throughput drug screening, and tissue engineering 
strategies [73]. Spheroids can be formed by creating an environment that favor cell-cell 
contact, such as the use of non-adhesive or positively charged substrates to decreases 
cell-surface contact [75, 78, 81]. External forces can also be applied to aggregate cells, 
such as in hanging drop culture that forms spheroids under microgravitational at the 
liquid-air interface [79] or the application of external magnetic fields [77, 82] and 
ultrasound [76], which are less common. To scale-up the formation of spheroids, 
dynamic culture in spinner flasks [75] or orbital rotary systems [71, 81] have been 
explored. Similarly, patterns of microfabricated structures, such as microwells, using 
non-adhesive materials have been used to increase the throughput of aggregate formation 
with applied fluid flow or low-speed centrifugation to deposit cell suspension into each 
micro-cavity [83-88]. In addition, this technique confers the advantage of control over 
size and uniformity [73, 88, 89] and easily allows homogeneous incorporation of 
microparticles within the spheroid [80, 90].        
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 Scaffold-free spheroid culture of MSCs is of particular interests due to the 
reported loss of self-renewal capability and differentiation potential in monolayer culture 
[74]. Not only so, the lack of similarity between a two dimensional substrate and the 
native stem cell niche has resulted in limited ability to improve differentiation efficiency 
in vitro [91]. Subsequently, the capability of MSC spheroids to maintain multipotency 
and improve differentiation has been investigated. In one study, MSCs retrieved from 
spheroids (300, 600, or 1,000 cells) and plated on a two dimensional substrate under 
differentiation cues demonstrated increased adipogenic and osteogenic differentiation 
potential than monolayer-expanded MSCs [80]. Furthermore, attempts to adipogenically 
or osteogenically differentiate MSCs in the three dimensional culture format has shown 
comparable increases in ECM markers [80] or higher gene and ECM expression in 
spheroids to MSCs in monolayer [74, 91]. Chondrogenic differentiation of MSC 
spheroids (~200μm) displayed increased SOX9, collagen II, and aggrecan gene 
expression compared to large pellets (>500μm) [70]. Not only was increased GAG and 
chondrogenic ECM protein deposition evident in the spheroids, but more homogenous 
expression was observed, suggesting that diffusional limitations in large multicellular 
aggregates may result in spatial heterogeneity in chondrogenesis [70]. Similar culture 
conditions with chondrocyte spheroids also promoted re-differentiation with increases in 
GAG production and collagen II gene expression [92]. Together, these evidence indicate 
that the three dimensional nature and small size of MSC spheroids may be more 




In addition to enhancing differentiation capacity, MSC spheroid culture has 
exhibited other benefits, such as improved therapeutic properties. For instance, injection 
of MSC spheroids into a rat acute myocardial infarction model resulted in significantly 
higher left ventricular function after 12 weeks compared to treatment with dissociated 
MSCs [93]. Besides the maintenance of strong viability and lack of necrotic core [74, 
80], MSC spheroids has been shown to secrete a variety of therapeutic cytokines [74, 94, 
95]. Frith et al. has reported decreased viability of four different cancer cell lines after 
culture in media conditioned by MSC spheroids, which secreted  increased amounts of 
tumor-suppressing interleukin-24 [74]. MSC spheroids also produced higher amounts of 
anti-inflammatory proteins (tumor necrosis factor α (TNFα) stimulated gene/protein 6 
and staniocalcin-1) and anti-cancer proteins (interleukin-24, TNFα-related apoptosis 
inducing ligand and CD82) compared to monolayer MSCs, which led to increased 
suppression of inflammatory response in vitro and in vivo in a mouse peritonitis model 
[94]. Another anti-inflammatory molecule, prostaglandin E2, has also been identified in 
MSC spheroid-conditioned medium as a contributor to reduced macrophage 
proinflammatory activity [95]. The secretome profile of MSC spheroids further 
demonstrates the therapeutic potential of MSC beyond enhancing differentiation 
potential. 
GAG-based Hydrogels for Cartilage Tissue Engineering 
 While a variety of polymers have been used to form hydrogel scaffolds for 
cartilage regeneration [37], GAGs is a particularly promising class of biopolymer due to 
their ability to interact with growth factors and attract water [18]. Because GAGs are 
abundant in native cartilage [12], GAG-based scaffolds may hold the potential to better 
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mimic the tissue structure and function. The hydrogels as discussed here are crosslinked, 
hydrophilic, polymeric constructs that have a high affinity for water [96] and have not 
undergone specific processing to create macropores or extensive interconnected porous 
structures.  Due to the wide range of GAG-based hydrogels, examples are organized by 
each major GAG species, starting with the most heavily sulfated. 
Heparin 
 Because of the high degree of sulfation along the GAG backbone, heparin-based 
scaffolds are often used in tissue engineering to sequester growth factors although 
heparin is only present in a few tissues natively [97]. In hydrogel scaffolds, heparin has 
often been combined with another polymer, such as linear or branched poly(ethylene 
glycol) (PEG) to improve handlability or tune protein release properties [98, 99]. For 
crosslinking, heparin has been functionalized with moieties such as thiols, maleimide and 
tyramine to react with PEG [14, 99, 100].  Due to the versatility of these crosslinking 
schemes, heparin can be used as a part of strategies to regenerate target tissues with very 
different biochemical and mechanical properties [101].  
 Heparin-PEG systems have been utilized for engineering tissues that require 
higher elastic moduli, such as in cartilage (tissue modulus ~1,000kPa) [14]. However, the 
moduli of the heparin-PEG hydrogels discussed here are still significantly lower than that 
of the native tissue and thus, they are may be not useful for load bearing applications 
without additional mechanical support. For repair of connective tissues, bovine 
chondrocytes have been delivered for cartilage repair in dextran-heparin hydrogels. In 
these studies, the increase in dextran content resulted in scaffolds of higher storage 
modulus up to a maximum of 48kPa [14]. However, scaffolds containing 25:75 weight 
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ratio of dextran and heparin demonstrated less susceptibility to hydrolytic degradation 
due to the stability of the urethane bond against hydrolysis [102] and enhanced collagen 
II and aggrecan gene expression and collagen production in chondrocytes compared to 
50:50 or 75:25 dextran-heparin scaffolds [14].  
 Overall, the ease in functionalizing heparin for crosslinking, as well as its high 
level of negative charge, has promoted its use in many tissue-engineering constructs as 
carriers for both cells and growth factors or other proteins.  In recent studies, heparin-
based hydrogels have also been explored to enhance cell-derived (autocrine) signals or 
paracrine signaling between two cell types in order to improve differentiation of 
encapsulated progenitor cells.  Thus, the electrostatic interactions between heparin and 
proteins can be employed in several paradigms in tissue engineering scaffolds as a part of 
regenerative approaches to a wide range of tissues. 
Chondroitin Sulfate 
 Chondroitin sulfate is the major GAG component of cartilage ECM [16] and has 
the ability to bind to positively-charged proteins due to the sulfate groups along the 
backbone. However, CS hydrogels are not often used as stand-alone drug delivery depots, 
but are utilized to  enhance the biochemical properties in the presence of growth factors, 
such as TGF-β, in cell culture media [103, 104]. CS is commonly paired with 
poly(ethylene glycol) (PEG) in constructs [103, 104].  To form hydrogels, CS is usually 
methacrylated for chemically crosslinking via free radical polymerization with either 
thermal [103, 105] or UV-light initiation [104, 106] in addition to crosslinking with 
carbodiimide chemistry [107, 108].  
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CS-based scaffolds have been designed to either: 1) induce chondrogenic 
differentiation of stem cells such as MSCs or 2) promote survival and function of 
differentiated chondrocytes while enhancing the tensile and compressive properties of the 
construct.  CS in combination with various PEG crosslinkers has been used to seed 
human MSCs (hMSCs) [103, 104]. One study examined the effects of desulfated CS on 
TGF-β sequestration from the media and hMSCs chondrogenic differentiation. The 
results showed that aggrecan and collagen II gene expression increased in the desulfated 
scaffolds compared to those containing natively-sulfated CS [103]. However, little 
degradation in the scaffold occurred, possibly preventing ECM deposition [103]. In 
contrast, in another study, a cell-laden CS methacrylate-PEG-diacrylate (PEG-DA) 
scaffold experienced degradation due to cell-secreted enzymes that allowed caprine 
MSCs (cMSCs) to form cartilaginous aggregates after 3 weeks with enhanced GAG and 
collagen production compared to a PEG-DA only scaffold [104]. The addition of CS 
increased the swelling ratio and the equilibrium water content of the hydrogels relative to 
PEG-dimethacrylate (PEG-DMA) scaffolds. To increase control over degradation, a 
MMP-sensitive sequence was added to a CS-PEG-DMA hydrogel, which resulted in a 
scaffold that mimicked the superficial zone of cartilage. The CS-PEG-MMP peptide 
hydrogel promoted high collagen II synthesis in the encapsulated cMSCs and low GAGs 
production level after 6 weeks [106].  
CS-based hydrogels have also been utilized to promote function of differentiated 
cells, such as chondrocytes, for cartilage tissue engineering.  In order to increase swelling 
ratio while maintaining high modulus in the hydrogel scaffold, CS methacrylate was 
photocrosslinked with PEG-DMA and used to encapsulate bovine articular chondrocytes 
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[109]. Compared to a PEG-DMA scaffold of similar swelling ratio, the incorporation of 
40% CS increased the compressive modulus of copolymer construct by 4 fold [109]. 
After 14-day culture, the bovine chondrocytes in CS-PEG hydrogels exhibited higher 
collagen II gene expression than pure CS constructs [109]. A decrease in GAG content 
was observed at week 4 in CS-PEG hydrogels compared to PEG-DMA controls, which 
may indicate possible degradation by cell-secreted enzymes [109].     
Other CS-based hydrogel scaffolds function not only as an artificial ECM to 
promote cellular activity, but as a tissue adhesive that can be loaded with bone marrow 
aspirates and BMP-2 for orthopedic tissue repair [108, 110]. The articular cartilage tissue 
adhesive was first formulated with methacrylated CS and PEG-DA, which could be 
photocrosslinked in situ and has the capability to bond other biomaterials containing 
vinyl groups [111]. CS was conjugated to n-hydroxysuccinimide (CS-NHS) to react with 
PEG-amine through the carboxyl group or with the primary amines found in the proteins 
of the tissue [108]. The multifunctional CS-PEG hydrogel can be polymerized in situ and 
is degradable enzymatically by chondroitinase ABC [112], which may better promote in 
vivo tissue integration. Similarly, CS-NHS was reacted with the amines in the proteins of 
bone marrow (BM) aspirate to encapsulate bovine meniscal fibrochondrocytes [110]. In 
vitro, the CS-BM adhesive has been shown to promote total collagen production in 
encapsulated bovine chondrocytes and collagen I production in meniscus 
fibrochondrocytes.  
CS has mainly been studied as a means to enhance the function of cells in the 
presence of exogenous cues as well as improve the stiffness of hydrogels without 
sacrificing the high water content needed for cell encapsulation.  Thus, much like its 
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native function in cartilage, CS has been employed for both biochemical and structural 
reasons towards regeneration of the tissue. 
Hyaluronan  
 Unlike other GAGs, HA is nonsulfated and therefore its major biological activity 
is conferred through binding to specific cell surface receptors, rather than interactions 
with growth factors [113]. HA is a component of every connective tissue and possesses 
extremely high water binding capacity [113], which makes it a strong candidate for 
engineering cartilaginous tissues [114]. Similar to CS, HA is often incorporated in 
hydrogel scaffolds to achieve both high swelling ratios and compressive moduli [115-
117]. HA is often methacrylated to allow for covalent crosslinking into hydrogels [118, 
119].  
HA has been incorporated for engineering of orthopedic tissues. Chondrogenic 
differentiation of caprine MSCs (cMSCs) has been investigated in PEG-HA scaffolds 
over 6 weeks [120]. The presence of HA suppressed GAG deposition in the cMSCs and 
induced lower levels of SOX9, aggrecan, and collagen II gene expression than PEG-DA 
controls and PEG-collagen scaffolds, which indicated a lack of chondrogenic phenotype 
[120].  However, the cMSCs in the PEG-HA hydrogel stained strongly for Alizain Red 
and promoted the highest calcium accumulation compared to the PEG-DA and PEG-
collagen hydrogels [120]. Degradation of the PEG-HA scaffold was not specifically 
discussed in the study [120].  
Like CS, HA-based hydrogel constructs have been employed due to both their 
high swelling capacity as well as the potential for bioactivity of HA degradation products 
through interaction with specific cell surface receptors. However, because HA is natively 
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found in many tissues, the range of applications for which HA hydrogels have been 
explored is greater than CS.  Like the other GAGs discussed in this section, the ability to 
tune levels of HA modification during synthesis allows the fabrication of crosslinked 
constructs with a range of mechanical properties and degradation times that can be 
tailored for particular regenerative medicine applications.    
Injectable Cartilage Tissue-Engineered Scaffolds     
 Many tissue-engineered hydrogels, such as the GAG-based systems detailed in 
the previous sections, are applicable to an injectable delivery, which offers several 
advantages over pre-formed scaffolds. An injectable approach to cartilage tissue 
engineering is attractive due to the ability of the delivered scaffold to fill to the irregular 
shape of cartilage defects and its amenability towards minimally invasive arthroscopic 
procedure [121, 122]. To confer injectability, the viscosity of the polymer solution should 
allow for conformation to defect morphology and retention at the injection site prior to in 
situ crosslinking with minimal release of cytotoxic by-product [122-124]. As a result, the 
hydrogel scaffold is usually characterized in terms of gelation time and how the 
crosslinking mechanism impacts the mechanical properties and degradability of the 
scaffold. Naturally-derived polymers, such as alginate, fibrin, and chitosan, have been 
studied due to their inherent biocompatibility and biodegradability [123]. However, to 
improve mechanical properties and handability of hydrogel scaffolds, combinations of 
natural and synthetic polymers have also been developed.     
 Alginate was one of the first biopolymers to be used as injectable scaffold for 
chondrocytes and it has been shown to promote GAG production after 12 week 
implantation in mice [33, 36]. More recently, an alginate system that can be rapidly 
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crosslinked under 1 min with a Young’s modulus of 0.17MPa promoted GAG and 
collagen II production in the encapsulated chondrocytes  after 6 weeks of in vitro culture 
[125]. Despite the ease of crosslinking, the degradability of alginate has not been shown 
in vivo, which is not favorable for tissue integration during the cartilage regeneration 
process [126]. Conversely, a degradable fibrin mesh, which can be formed from 
autologous fibrinongen and thrombin, has been used as injectable glue for various tissues 
[126, 127] that gelates between 1 to 10 minutes [128]. After crosslinking, fibrin gels has a 
dynamic compressive modulus up to 4-5kPa [129] and an equilibrium modulus of 
~12kPa [130], which are much lower than the mechanical properties of native cartilage. 
Fibrin gel has been shown to promote collagen II and SOX9 gene expression as well as 
GAG production in chondrocytes [129, 130]. Although in vivo study has demonstrated 
that the implanted fibrin gel can enhance GAG and collagen II production after 6 weeks 
[127], the low mechanical property and high degradability of fibrin scaffolds may not be 
ideal for engineering cartilage tissue [131].  
 Other naturally-derived polymers, such as chitosan, can be modified to allow for 
in situ crosslinkning with different schemes to form injectable hydrogels. A mixture of 
methacrylated chitosan-glycol and HA was photocrosslinked under 40 seconds, resulting 
in a scaffold of ~17kPa compressive modulus that underwent little hydrolytic degradation 
but high enzymatic degradation (~20 wt% remaining) after 42 days [132]. Alternatively, 
an N-succinyl-chitosan and aldehyde HA hydrogel was crosslinked under 4 min without 
additional chemical crosslinker based on a Schiff base reaction between the amino and 
aldehyde groups, achieving compressive modulus up to 28kPa with slower hydrolytic 
degradation as the amount of chitosan increased [133]. These chitosan-HA systems 
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demonstrated more safranin-o and alcian blue staining after 21 days than chitosan-only 
controls [132] and maintained viability of encapsulated chondrocytes [133]. Enzymatic 
crosslinking using horseradish peroxidase and hydrogen peroxide is an alternative 
method to produce injectable hydrogels composed of tyramine-conjugated heparin and 
dextran with encapsulated chondrocytes [14]. The gelation time was as low as 30 sec and 
the resulting scaffold possessed a storage moduli of 48kPa and increased CS and collagen 
production [14]. In a similar dextran-tyramine system without heparin, the hydrogel 
polymerized within 5 to 9 min with little hydrolytic degradation (less than 25 wt% loss) 
in 5 months [102].  
 Synthetic polymers, such as oligo(poly(ethylene glycol) fumarate) (OPF) and 
PEG, can be combined with biopolymers or used alone for injectable hydrogels. An OPF 
scaffold containing TGF-β1-loaded gelatin microparticles formed with a PEG-DA 
crosslinker under radical polymerization exhibited an elastic modulus of 20kPa [134] was 
able to maintain the chondrocytic phenotype for 21 days [135] and increase collagen II 
gene expression in MSCs after 14 days [136]. In another hydrogel system, PEG-
vinylsulfone and HA-thiol were crosslinked via Michael-type addition under 1 min with a 
storage modulus of 1kPa showed tunable enzymatic degradation rate between 3 to 15 
days and the encapsulated chondrocytes deposited GAG and collagen II after 3 weeks 
[137]. These hybrid injectable hydrogels employ the inherent properties of the naturally-
derived polymer to enhance aspects of the system: the use of gelatin to electrostatically 
load TGF-β [135] and HA to increase swelling of the hydrogel [137]. In contrast, a PEG-
only transdermal photopolymerizable hydrogel (~10kPa) was used to encapsulate 
chondrocytes and implanted in nude mice [138]. After 7 weeks, collagen II production 
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and GAG deposition were detected in the hydrogel. Other synthetic polymers have been 
developed, such as a urethane-based prepolymer composed of (diisocyanato poly 
(ethylene glycol) and monohydroxl dimethacrylate poly (ε-caprolactone) triol, that can be 
photopolymerized to achieve a relatively high compressive modulus of ~110kPa [139]. 
However, little hydrolytic degradation was observed while enzymatic degradation 
occurred with 56 wt% over 28 days. After 8 weeks of culture, chondrocytes adhered to 
beads encapsulated in the polyurethane hydrogel deposited GAG and collagen II in both 
static and spinner flask culture [139].  
 One recent development in injectable cartilage tissue engineering is a scaffold-
free approach, which presents the possibility of increasing the amount of therapeutic dose 
of cells by reducing the volume of polymer delivered. As described in previous sections, 
MSCs have been cultured as spheroids (100-500μm) that are small enough to pass 
through a needle without damage or loss of viability due to the shear force [93] and thus, 
can be used as an injectable cartilage tissue engineering strategy. Such approach is also 
attractive in the possibility of improving retention at the injection site compared to single 
cells. Additionally, material-based physical stimuli, such as microparticles, can still be 
incorporated and presented within the spheroids [140]. Due to its capacity for injectable 
delivery, ability to better mimic the physiological tissue structure [73] and maintenance 
of high differentiation potential, MSC spheroids cultured under chondrogenic conditions 
were investigated in this study.  
Purpose of Thesis Project 
The purpose of this project was to investigate the incorporation of CSMA 
microparticles in hMSC spheroids and how the presentation of the GAG within a 
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multicellular environment may affect chondrogenic differentiation. The first goal was to 
characterize the effects of CSMA microparticle incorporation on physical changes in the 
MSC spheroids. The incorporation efficiency of the microparticles was determined for a 
range of MP:cell number ratios. Analysis of MSC spheroid volume changes under 
chondrogenic culture conditions and the highest MP:cell number ratio (3:1) was also 
performed. General morphological effects of MP incorporation on the aggregates were 
studied with histological staining.  
The second goal was to examine the extent of chondrogenic differentiation in 
hMSC spheroids and whether CSMA microparticles can promote MSC chondrogenesis in 
the presence of the exogenous cue TGF-β1. Microparticles have been cultured within 
multicellular aggregate in previous studies in order to introduce differentiation cues in a 
more uniform manner [90]. A number of studies have also investigated the effects of 
PLGA, PEG, and gelatin microparticles on the chondrogenic differentiation of larger 
MSC pellets [141-143]. However, chondrogenesis in small MSC aggregates containing 
microparticles has not been previously investigated. We have also demonstrated for the 
first time, the use of CS-based microparticles in the attempt to differentiate MSCs.  Due 
to the ability of CS-based hydrogel scaffolds to promote chondrogenesis in MSCs [103, 
104, 106, 144-146], we hypothesize that the incorporation of CSMA microparticles in the 
presence of TGF-β1 will more effectively promote cartilaginous ECM deposition and 
organization in hMSC spheroids. Specifically, MSC spheroids with or without 
incorporated CSMA microparticles were cultured in media containing soluble TGF-β1 
for 21 days under hypoxia (3% O2). MSC spheroids without MPs cultured in media 
without TGF-β1 served as a negative control.  Changes in GAG deposition were analyzed 
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with histology. Gene expression of chondrogenic markers was determined with 
quantitative reverse transcription polymerase chain reaction and chondrogenic ECM 




































Portions of this chapter were adapted from Miller, T., Goude, M. C., McDevitt, T. C., & 
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MATERIALS AND METHODS 
Chondroitin Sulfate Methacrylate Microparticle (CSMA MP) Fabrication  
CSMA was synthesized by reacting chondroitin sulfate-A with methacrylic 
anhydride (Sigma-Aldrich) and sodium hydroxide in order to conjugate methacrylate 
groups to the native hydroxyl groups that are present on the N-acetylgalactosamine of the 
CS [146]. CSMA MPs of ~10μm diameter were prepared using a water-in-oil, single 
emulsion technique, as described previously [146]. CSMA (55.6mg) was dissolved in 
440μL of PBS and mixed with ammonium persulfate (30 µL, 0.3 M) (Sigma-Aldrich) 
and tetramethylethylenediamine (30 µL, 0.3 M) (Sigma-Aldrich). The mixture was added 
dropwise to corn oil (60mL) with 2mL of Tween 20 and homogenized at 3,800rpm for 5 
minutes. The mixture was then stirred and heated to 50°C under N2 purging for 
crosslinking. After 30 minutes, the mixture was centrifuged at 3000rpm at 4°C to isolate 
the MPs. Following the removal of the corn oil, the MPs were washed 3 times with 
ddH2O. Prior to incorporation in MSC spheroids, the MPs were incubated in 90% ethanol 
on the rotary at 4°C for 1 hour and washed with ddH2O. The supernatant was removed 
from the MPs before lyophilization.  
Chondrogenic Mesenchymal Stem Cell (MSC) Spheroid Culture 
MSC Expansion 
All cell culture reagents were acquired from Mediatech unless otherwise noted. 
Human bone marrow mesenchymal stem cells from 3 donors were obtained from the 
Texas A&M Health Science Center (Temple, TX). Passage 2 MSCs from each donor was 
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plated separately at low density (100 cells/cm
2
) and expanded in growth medium 
composed of Minimal Essential Medium-alpha (α-MEM), 16.3% fetal bovine serum 
(Atlanta Biologicals, Lawrenceville, GA), 1% antibiotic/antimycotic and 1% L-glutamine 
until confluency under normixa (37°C at 5% CO2 and 20% O2). MSCs were then 
trypsinized and cells from all 3 donors were pooled prior to spheroid formation.  
MSC Spheroid Formation  
MSC spheroids were formed as previously described by forced aggregation using 
400x400μm agarose microwell inserts [83, 90]. A single cell suspension of MSCs 
(4.2x10
6 
cells/mL) was added to the microwell inserts and centrifuged at 200g for 5 
minutes to deposit cells into the individual wells. The cells were incubated for 18 hours to 
allow aggregation under normoxia (37°C at 5% CO2 and 20% O2). The MSC spheroids 
were removed from the inserts using a wide-bore pipette for subsequent alginate 
encapsulation. MSC spheroids containing CSMA MPs were formed similarly; a pre-
mixed suspension of MPs and cells (3:1 number ratio) was added to the agarose 
microwell inserts followed by a similar centrifugation and overnight incubation. Our 
previous study indicated that incorporation of MPs in embryonic stem cell aggregates at 
these MP:cell ratios was not detrimental to the maintenance of cell-cell contact or the 
distribution of MPs within the aggregate [147]. 
Spheroid Culture and Retrieval 
After formation, MSC spheroids were suspended in 1.5% sodium alginate 
(Spectrum Chemical, Gardena, CA), which was crosslinked in a 100mm petri dish using 
a pre-cut filter paper (90mm diameter) to uniformly distribute 100mM calcium chloride 
(EMD, Darmstadt, Germany) across the surface, resulting in a thin layer (~1mm 
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thickness) that remained immobilized on the dish surface throughout the study. Alginate 
encapsulation was necessary to prevent agglomeration of MSC spheroids during extended 
culture periods (>4 days).   
MSC spheroids suspended in alginate were cultured in serum-free medium 
containing high glucose Dulbecco’s Modified Eagle Medium (DMEM), 1% non-essential 
amino acids, 1% antibiotic/antimycotic, 1% insulin, human transferrin, and selenous acid 
(ITS+) premix (BD Biosciences, San Jose, CA), 50μg/mL ascorbate-2-phosphate (Sigma-
Aldrich) and 100nM dexamethasone (Sigma-Aldrich) under hypoxic conditions (37°C at 
5% CO2 and 3% O2) for 21 days. For chondrogenic culture, 10ng/mL TGF-β1 
(Peprotech, Rocky Hills, NJ) was added to the medium and is designated as +TGF-β in 
subsequent sections. 
During culture the alginate layesr were dissociated with 55mM sodium citrate 
(Sigma-Aldrich, St. Louis, MO) and re-formed using the aforementioned method every 7 
days of culture to minimize degradation of alginate. At experimental time points, the 
alginate layers were dissociated with sodium citrate and washed with phosphate buffer 
solution in order to collect samples for subsequent analysis at day 1, 7, 14, and 21.   
Morphological and Chondrogenic Analyses 
Spheroid Volume Analysis 
MSC spheroids were imaged at day 1 and 21 using a phase contrast microscope 
(Nikon Eclipse TE2000-U, Tokyo, Japan). A minimum of 5 images with multiple 
spheroids per field (~10 spheroids/field) were taken for each experimental replicate. 
Spheroid diameters were measured using the ImageJ (v. 1.47) straight line selection tool 
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and used to calculate the volume, assuming perfect spheres. The volume data were 
normalized using the Box-Cox transformation  prior to statistical testing [148].  
Histological Staining 
MSC spheroids were retrieved from the alginate hydrogels at day 1, 7, 14, and 21 
and fixed in a 10% formaldehyde solution for 30 minutes for histological analysis. Fixed 
samples were immersed in 5% w/v sucrose solution (EMD, Darmstadt, Germany), before 
subsequently being replaced with increasing sucrose solution concentrations up to 15%, 
under vacuum (-25inHg). Samples were then vacuum-infiltrated with increasing 
concentrations of 20% sucrose:optimal cutting temperature compound (OCT) solutions 
(4:1 to 1:2 volume ratios). After overnight infiltration, samples were embedded in OCT 
and allowed to solidify for 10 minutes in a mixture of dry ice and 100% ethanol. Samples 
were stored at -80°C and cryosectioned at 10μm thickness (Thermo Scientific, Cryostar 
NX70) prior to staining with either hematoxylin and eosin (H&E) or Safranin-O. 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
MSC spheroids were collected for gene expression on 1, 7, 14, and 21 days and 
lysed with RLT Lysis Buffer (Qiagen, Hilden, Germany). The cell lysates were further 
filtered with the QIAshredder tissue homogeneizer (Qiagen) and RNA was extracted with 
the RNeasy Kit (Qiagen). Reverse transcription was performed with iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules, CA) using the T100 Thermal Cycler (Bio-Rad). 
Primers (Invitrogen) were custom designed to target human mRNA for β-actin, SOX9, 
collagen II, aggrecan, collagen I, collagen X, myoD and runt-related transcription factor 
2 (RUNX2) as shown in Supplementary Table 1. Quantitative polymerase chain reaction 
(PCR) was performed using the SYBR Green Master Mix (Life Technologies). The raw 
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fluorescence data was first processed in LinReg PCR software to more accurately 
determine individual PCR efficiency and mRNA starting concentration (v13.1; 
http://www.hartfaalcentrum.nl) [149]. Fold regulation relative to the untreated Day 1 
control was determined for each sample with 18S ribosomal protein and β-actin as 
endogenous housekeeping controls. The Box-Cox transformation was used to normalize 
the PCR amplification data of each gene for subsequent statistical analysis [148].  
 
Table 1. Primer sequences of MSC gene markers  
Target Marker  Primer Sequences (5’→3’) GenBank 





     
















































Immunostaining for ECM deposition in cryosectioned samples was performed 
using primary antibodies for type I, II, and X collagen, aggrecan, and α-smooth muscle 
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actin (α -SMA).  Antigen retrieval was performed for all sections by incubating in 20 
μg/ml proteinase K (Sigma-Aldrich) for 10 minutes at 37°C.  Samples for aggrecan and 
collagen X immunostaining were deglycosylated with 0.75U/mL chondroitinase ABC 
(Sigma-Aldrich) for 1.5 hours at 37°C. Samples were blocked with Image-iT FX Signal 
Enhancer (Life Technologies, Carlsbad, CA) and incubated with the primary antibodies 
(for dilutions, see Supplementary Table 2) overnight at 4°C.Secondary antibody binding 
with Alexa Fluor 488-conjugated goat polyclonal anti-mouse immunoglobulin G (IgG, 
Molecular Probes, Carlsbad, CA) or IgM (Molecular Probes) was performed at room 
temperature for 1 hour. The samples were stained with Hoechst (Sigma-Aldrich) to 
visualize the nuclei. Isotype controls were similarly stained using a monoclonal mouse 
IgG1(Abcam) or IgM (Abcam) isotype antibody (data not shown).  
Table 2. IHC antibody information 
1° Antibody Catalog Number Isoform Dilution Deglycosylate 
Aggrecan Abcam (ab3778) IgG 1:20 Y 
α-SMA Dako (IS61130-2) IgG None N 
Collagen I Abcam (ab90935) IgG 1:60 N 
Collagen II Abcam (ab3092) IgG 1:20 N 
Collagen X Sigma (C7974) IgM 1:20 Y 
IgG Isotype Abcam (ab91353) IgG 1:10 N 
IgM Isotype Abcam (ab18401) IgM 1:50 N 
 
Statistical Analysis 
A two-factor analysis of variance (ANOVA) with Tukey’s post hoc multiple 
comparison test (p≤0.05) was performed on the data from the spheroid volume and RT-
PCR analyses to determine statistical significance between samples using Minitab 






Effect of TGF-β and CSMA MPs on MSC Spheroid Size 
The incorporation efficiency (~80%) of CSMA MPs in MSC spheroids was 
independent of the initial amount loaded up to 3:1 MP:cell number ratio (Fig. A1).  The 
highest ratio (3:1) that yielded ~1,600 MPs per spheroid was used for this study in order 
to maximize any potential chondrogenic effects of the CSMA MPs without 
compromising the formation of the aggregate. Representative phase images from each 
culture condition are shown in Fig. 1. On day 1, there was no difference in volume 
between untreated spheroids and spheroids containing only MPs or TGF-β (Fig. 1I), but 
the +MP +TGF-β spheroids had the largest volume (0.009mm
3
) and were almost 2 times 
larger than the other spheroids. After 21 days, the +MP +TGF-β spheroids had the largest 
volume (0.016mm
3
) and were approximately 2 times greater than that of the +MP 
spheroids (~0.008mm
3
) (Fig. 1J). The +TGF-β spheroids also exhibited slightly larger 
volume (~1.2x) than the +MP group. Regardless of MP incorporation, spheroids cultured 
in chondrogenic conditions experienced a greater increase in volume (~2-3x) compared to 
spheroids in non-chondrogenic conditions (~1.8-2x).  
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Figure 1. Changes in MSC spheroid volumes in response to MP incorporation and TGF-β. Differences in 
MSC spheroid sizes for each culture condition and over 21 days was observed in representative phase 
images (A-H). At day 1, the volume of +MP +TGF-β spheroids was significantly greater than all other 
groups (I). At day 21, the volume of all groups differed significantly from each other (J). npopulation=3, 
nspheroid=150, * indicates significantly different from same treatment at Day 1 (p<0.05).  
+
 indicates 
significantly different from the +TGF group (p<0.05). 
&
 indicates significantly different from all other 
groups (p<0.05). Scale bar = 200μm. 
 
CSMA MP Clustering and Morphological Changes in MSC Spheroids 
Clustering of CSMA MPs near the center of the MSC spheroids was observed 
with or without TGF-β as early as day 7 in H&E staining (Fig. 2F, H, J, L).  Particularly 
in the +MP +TGF-β spheroids, the cell nuclei exhibited pronounced elongation and 
circumferential alignment around the core of MPs at day 14 and 21 (Fig. 2H, L, arrows). 
The presence of GAG was detected in the ECM of +TGF-β spheroids at day 14 and 21 
(Fig. 2S, W, arrows) by Safranin-O staining. GAG presence was also observed in the 
region of organized cells and ECM around the MP core in +MP +TGF-β spheroids at day 
21 (Fig. 2X, arrows), but was absent in the +MP spheroids (Fig. 2V, arrows). Due to the 
lack of evident biochemical response of MSCs to the CSMA MPs without TGF-β, the 





Figure 2. Histology shows differences in MSC spheroid morphology over 21 days. Cell morphology and 
organization changes in response to MP or TGF-β were observed in H&E staining (A-L). Presence of 
GAGs in the CSMA microparticles or in the ECM was confirmed by Safranin-O staining (red) (M-X). Fast 





Increase in MSC Chondrogenic Gene Expression with TGF-β and CSMA MPs 
Gene expression of the chondrogenic transcription factor SOX9 was significantly 
higher in the +MP +TGF-β spheroids (1.4±0.3 fold increase) than the untreated group at 
day 7, but decreased at day 21 (0.6±0.2) (Fig. 3A). The +TGF-β spheroids exhibited a 
gradual increase in the gene expression of aggrecan from day 7 to day 21 with a 6.7±0.7 
fold increase at day 21 compared to the untreated (Fig. 3B). Similarly, collagen II 
expression in +TGF-β spheroids was increased at day 14 (1.6±0.7 fold increase) and day 
21 (44±18 fold increase) (Fig. 3C). The +MP +TGF-β spheroids also demonstrated 
increases in aggrecan and collagen II gene expression, but the presence of the MPs 
resulted in earlier peaks (4.8±1.4 and 101±10 fold increase, respectively) by day 14 
compared to the untreated spheroids.  
In addition to promoting chondrogenic markers during differentiation, minimizing 
the expression of collagen I and X, which are indicative of the undesired 
fibrocartilaginous and hypertrophic phenotypes, is important. Collagen I expression was 
slightly increased by 1.5 fold at day 7 and sustained until day 21 in the untreated 
spheroids whereas in spheroids containing MPs and TGF-β, a 1.7 fold increase was not 
observed until day 14 (Fig. 3D). No significant change in collagen I gene regulation was 
found in the +TGF-β spheroids over time (Fig. 3D). The expression of collagen I was 
similarly elevated (~1.7 fold increase) in both the +MP +TGF-β and untreated spheroids 
at day 14. However, the presence of MPs in MSC spheroids with TGF-β resulted in a 
0.6±0.1 fold decrease in collagen I expression at day 21 relative to the untreated group. 
For collagen X expression, the untreated spheroids demonstrated a gradual increase over 
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time, reaching a 5.7 fold increase at day 21 (Fig. 3E). In the +TGF-β spheroids, a 52 fold 
increase in collagen X regulation was observed by day 7 and sustained until day 21 (66±6 
fold increase) while the addition of MPs in the spheroids promoted a large increase 
(81±17 fold increase) by day 14 followed by a sharp reduction at day 21 (12±3 fold 
increase). No significant difference in the elevated collagen X expression was detected 
between +TGF-β and +MP +TGF-β spheroids at day 14, but the addition of MPs resulted 
in slightly less pronounced increase compared to the untreated spheroids at day 21.  
 
 
Figure 3. Expression of chondrogenic ECM gene markers by MSC spheroids in response to TGF-β and 
CSMA microparticles. Gene expression of SOX9 remained relatively constant over 21 days (A). The 
addition of TGF-β with or without CSMA microparticles promoted the expression of aggrecan (B) and 
collagen II (C) by day 7. Slight increase in collagen I expression was observed in all groups (D) while large 
increase in collagen X expression occurred in all except the untreated group (E). n=3, * indicates 
significantly different from same treatment at Day 1.  
#
 indicates significantly different from the untreated 
at the same time point. 
+







ECM Organization and Deposition in MSC Spheroids  
At day 14, both groups cultured in TGF-β exhibited similar levels of increased 
staining for aggrecan compared to the untreated group (Fig. 4A-F). Collagen II staining 
was slightly stronger in the +TGF-β and +MP +TGF-β spheroids compared to untreated 
and there was no appreciable difference between the 2 groups (Fig. 4G-L). Collagen I 
appeared more organized in the +TGF-β spheroids and was distinctly aligned around the 
MP core in the +MP +TGF-β spheroids as compared to the amorphous staining in the 
untreated group (Fig. 4M-R, arrows). Some alignment of collagen X around the MP core 
could also be seen in the +MP +TGF-β spheroids compared to the other groups at day 14 
(Fig. 4S-X, arrows). The presence of α-SMA could be detected strongly at the borders of 
the untreated and +TGF-β spheroids with some weak pericellular staining in the center 
(Fig. 4Y-DD). However, the addition of MPs in the presence of TGF-Β greatly reduced 
the expression of α-SMA on the spheroid surface. 
By day 21, organized pericellular staining of aggrecan was present around 
elongated nuclei in +TGF-β and +MP +TGF-β spheroids (Fig. 5A-F). Collagen II 
staining was high in +TGF-β spheroids, but slightly reduced with the incorporation of 
MPs (Fig. 5G-L). Similar amounts of positive staining for collagen I and X was observed 
in the +TGF-β and +MP +TGF-β spheroids (Fig. 5M-R, S-X). In the +MP +TGF-β 
spheroids, strong positive collagen I staining was observed on the periphery of the MP 
core and near the individual MPs at day 21 (Fig. 5O, R, arrows). Organization of collagen 
I around the MP core was still obvious after 3 weeks of culture and was also evident in 
collagen X staining (Fig. U, X, arrows). The presence of α-SMA on the spheroid surface 
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was observed in all groups, but the +TGF-β spheroids exhibited additional pericellular 
staining in the center compared to the +MP +TGF-β group at day 21(Fig. 5Y-DD). 
 
Figure 4. Immunofluorescence staining for deposition of chondrogenic ECM molecules in MSC spheroids 
at day 14. Positive aggrecan and collagen II staining were detected in all except the untreated group (A-F, 
G-L). Similar levels of collagen I and X were present in all groups (M-R, S-X) while differences were 





Figure 5. Immunofluorescence staining for deposition of chondrogenic ECM molecules in MSC spheroids 
at day 21. Positive staining for aggrecan was detected in all groups, but collagen II staining was still absent 
in the untreated group (A-F, G-L). Collagen I levels in the untreated spheroids was low, but collagen X 
staining was similar between all groups (M-R, S-X). α-SMA staining was also observed across all culture 




A comparison between day 14 and 21 IHC showed no appreciable changes in the 
amount of aggrecan staining detected in +TGF-β spheroids or in +MP+TGF-β samples.. 
Collagen II appeared to increase in +TGF-β spheroids over time, while little change was 
seen in the +MP +TGF-β spheroids. No difference was observed in collagen I and X 
staining between day 14 and 21 in +TGF-β spheroids or in +MP +TGF-β spheroids., An 
apparent reduction in the area of positive α–SMA staining on the surface of untreated and 
+TGF-β spheroids along with decreased pericellular staining in the center occurred 
between days 14 and 21. Although the +MP +TGF-β spheroids exhibited a slight increase 
in the presence of α–SMA on the surface between days 14 and 21, the amount of α–SMA  


















We have demonstrated the ability to incorporate GAG-based MPs in hMSC 
spheroids for chondrogenic differentiation in this study. Specifically, MSC spheroid 
volume was significantly enhanced by the combination of CSMA MPs and TGF-β, which 
also exhibited a unique organization of cells and ECM around the MP core. Some 
evidence of earlier chondrogenic differentiation in the spheroids with MPs was observed 
at the gene expression level (aggregan and collagen II), although all samples with TGF-β 
treatment exhibited similar levels of GAG, aggrecan, collagen I, II, and X staining by 14 
days of culture. From the spheroid size analysis, the +MP +TGF-β spheroids were found 
to exhibit the largest volume at both days 1 and 21. Part of this large increase in volume 
could be attributed to the presence of the MPs. However, calculating the sum of 
theoretical total MP volume and the volume of a spheroid alone cultured in TGF-β at day 
1 and 21 still resulted in a ~20% and ~30% lower values, respectively, than that measured 
in the +MP +TGF-β spheroids, which indicates that the combination of CSMA MPs and 
TGF-β has more than a purely additive effect on the volume of MSC spheroids. In a 
comparable hMSC spheroid system without exogenous growth factors, size difference 
between spheroids with or without gelatin MPs was not observed at day 1 nor was any 
increase seen up to 7 days of culture [80].  
The incorporation efficiency for CSMA MPs was close to 100% for all three 
MP:cell ratios investigated (Fig. 1S), suggesting that the MSCs may have an affinity for 
and can easily interact with CS-based materials. As noted in a study in which PLGA, 
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agarose or gelatin MPs were incorporated in embryonic stem cell aggregates, differences 
were observed in incorporation efficiencies, which was attributed to the difference in 
material adhesiveness [90]. In addition to high incorporation, the CSMA MPs 
spontaneously clustered within the MSC spheroids by day 7 and remained as a core for 
the duration of the culture as shown by histology, which was not observed with 
polystyrene (PS) MPs (Fig. S2), even though, in this system, the PS microparticles had 
similar incorporation efficiencies as CSMA MPs (data not shown). Clustering of MPs in 
MSC pellet culture containing PEG, PLGA, or gelatin MPs has not been previously 
reported [141-143]. In previous studies, the diameters of the MPs ranged from ~6-7μm 
(PEG and PLGA) [141, 142] to ~15μm (gelatin) [143], which are comparable to the size 
of the CSMA MPs (~10μm). Because PLGA and PEG are synthetic materials, it might be 
expected that MSCs may interact with them differently than with the CS-based MPs. 
However, clustering was also not observed in MSC pellets that included gelatin particles 
when cultured up to 4 weeks [143]. Together with the volume analysis data, this suggests 
that there may be further interactions of MSCs specifically with CS-based particles that 
allow their movement and rearrangement in the spheroids after formation. Such 
interactions may affect overall cellular or ECM packing in the spheroids [143], that leads 
to a larger overall spheroid volume in the presence of TGF-β, even after only 1 day. 
While further studies are required to better understand the nature of any specific 
MSC–CSMA MP interactions in this system, it was observed that the MSC spheroids 
exhibited uniform circumferential organization of elongated cell nuclei and ECM around 
the clustered MP core as seen in the H&E (Fig. 2H, L) and IHC staining (Fig. 4R, X, 5R, 
X), particularly in the presence of TGF-β. Chondrocytes adopt a fibroblast-like 
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morphology with a spread and elongated appearance in monolayer culture  on two  
dimensional substrates [150]. Concomitant with the loss of a rounded phenotype, 
chondrocytes de-differentiate and decrease expression of aggrecan and collagen II, while 
increasing production of collagen I [151-154]. While de-differentiation may be a concern 
in this system due to the elongated cell morphologies observed in the +MP +TGF- β 
samples, no evidence was observed via gene expression analysis or IHC that would 
suggest this was occurring overall in these samples. Instead, the unique organization 
around the MP core has not been reported in previous pellet or spheroid and MP systems 
and presents a possible avenue for directing microtissue radial architecture from the 
inside-out to more closely mimic the zonal organization of tissues such as articular 
cartilage [5]. 
 To better understand the potential effects of this MP core on cellular organization, 
staining for α-SMA was performed. TGF-β1 has been shown to increase the α-SMA 
expression and contractility in human MSCs at 1ng/mL [155] and α-SMA production has 
also been detected in the outer region of MSC pellets [142, 155]. We saw a similar 
pattern of expression near the surface of all spheroids, which suggests that α-SMA 
expression may have resulted from the contractility exerted by the MSCs near the surface 
of the spheroid. Interestingly, there was a pronounced reduction of α-SMA protein on the 
border of +MP +TGF-β spheroids at day 14, showing that the CSMA MPs may have the 
ability to prevent TGF-β from inducing α-SMA expression mechanically by acting as a 
substrate that modulates cell contractility [155, 156]. A similar reduction of α-SMA 
staining from the border was seen in MSC pellets containing PEG MPs cultured in TGF-
β3-supplemented media [142], further indicating that the physical presence of MPs may 
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play an important role in mediating α-SMA production, possibly by disrupting cell-cell 
and cell-ECM interactions.  
Chondrogenic Characterization 
One of the problems with in vitro chondrogenic culture is potential hypertrophy, 
so the use of hypoxic culture is necessary to mitigate the undesired phenotype [55, 57, 
58].  The oxygen tension for chondrogenic culture has typically ranged from 1 to 5% O2 
[55-58], and, accordingly, the experiments in this study were performed at 3% O2. 
Although the +MP +TGF-β spheroids displayed similar levels of increased expression for 
chondrocytic genes (aggrecan and collagen II) as the +TGF-β spheroids, the +MP +TGF-
β spheroids showed highest expression levels 1 week earlier than the +TGF-β group for 
collagen II and aggrecan (Fig. 3B, C), which suggests that the CSMA MPs play a role in 
mediating the temporal sequence of TGF-β-induced chondrogenesis. CS has been shown 
to electrostatically interact with positively charged growth factors, such as TGF-β, and to 
modulate growth factor signaling during cartilage morphogenesis [157], so it is possible 
that the MP core could mediate the quantity and distribution of  TGF-β1 available to 
induce differentiation in our culture system, resulting in the earlier expression of 
cartilaginous genes by MSCs. We also noted that gene expression of negative lineage 
marker RUNX2 (osteogenic) was minimally increased in all spheroids over 21 days (Fig. 
S3A) and myoD (myofibroblastic) was decreased in all groups over 21 days (Fig. S3B).  
In order to determine the degree and location of deposition of each of ECM 
molecules tracked with RT-PCR,  IHC staining was used. In contrast to the gene 
expression data, which indicated earlier onset of differentiation for the MP laden group, 
both sets of TGF-β treated spheroids (with or without MPs) exhibited similar levels of 
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staining for aggrecan and collagen II protein deposition at day 14 and 21 (Fig. 4 and 5E, 
F, K, L). In addition, GAG staining for +TGF-β spheroids was observed earlier than the 
+MP +TGF-β group (Fig.  2W, X). Other hMSC pellet culture in hypoxia has also found 
increases in collagen II and aggrecan gene expression that was not reflected in protein 
production [158]. Increased expression and/or activity of proteases, in the +MP +TGF-β 
spheroids may provide another potential explanation for the difference.  
As mentioned previously, in addition to enhancing chondrogenic gene and ECM 
markers, another goal of in vitro MSC chondrogenesis is to minimize fibrocartilaginous 
and hypertrophic phenotypes, which can be detrimental for long-term articular cartilage 
restoration [53, 54]. Fibrocartilaginous collagen I gene expression was slightly elevated 
with spheroids cultured in TGF-β1 (Fig. 3D) similar to the increase seen in smaller 
micropellets under hypoxia [70]. Moreover, strong positive IHC staining was observed 
throughout the ECM at all timepoints in the spheroids as seen in hMSC micropellets [70] 
and larger MSC pellets without MPs [45, 70] or with PEG [142] and gelatin MPs [143]. 
Despite the reported ability of hypoxic culture to delay or suppress hypertrophy in pellets 
or encapsulated MSCs [55, 57, 58], ~80 fold increase in collagen X gene expression at 
day 14 found in TGF-β-treated spheroids with or without MPs was confirmed by IHC 
staining (Fig. 3E). Even under hypoxic conditions, increases in collagen X levels during 
chondrogenesis have still been reported in MSCs cultured in various formats [68-70], 
which demonstrates the difficulty in preventing hypertrophy in vitro. Mixed results were 
observed in previous work with MSC pellets containing MPs, where the incorporation of 
gelatin MPs led to collagen I mRNA levels similar to those seen in no MP controls [143], 
but PEG MPs reduced both collagen I and X gene expression [142]. These findings show 
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varying levels of effectiveness in suppressing collagen I and X expression between each 
study, which implies that other factors, such as aggregate size and MP type, may play a 
role in modulating MSC phenotype.  Thus, culture conditions for our specific system may 
need to be further optimized to reduce the fibroblastic and hypertrophic differentiation of 
MSCs.  
While the gene expression results are intriguing, it does not appear that the 
presence of the CSMA MPs enhanced deposition of cartilaginous ECM in this spheroid 
culture. There could be several explanations for this, including that the MP dose was not 
appropriate for differentiation, and that there was minimal degradation of the CSMA MPs 
observed in the MSC spheroids over 21 days.  While the MP:cell ratio was chosen to 
allow sufficient cell-cell contact to form spheroids while still incorporating sufficient 
GAG in the system, on a per cell basis, the concentration of CS in the spheroid is similar 
to the physiological concentration in the articular cartilage of the knee according to our 
calculations (data not shown). Despite the large number of CSMA MPs present within a 
spheroid, only a number of MPs on the surface of the core would be available for direct 
cell-GAG interaction, thus reducing the overall “dose” of GAG compared to CS-based 
hydrogels with encapsulated hMSCs, which contained ~6-10x higher amount of GAG per 
cells than native cartilage [144, 159]. The CSMA MPs induced similar levels of 
chondrogenesis as these CS-based hydrogels even at a lower “dose” of GAG, suggesting 
that the organization of the MPs, MSCs, and ECM within the aggregate may help 
maintain the chondrogenic differentiation potential as spheroid culture has been shown to 
preserve the ability of MSCs to commit to adipogenic and osteogenic lineages [80].  
There was also little degradation seen in the MPs over the course of the experiment, 
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which, in addition to non-uniform distribution of CS within the spheroid, would likely 
minimize release of any sequestered growth factors. In the future, the introduction of 
groups into CSMA MPs that promote degradation may allow a more homogeneous 
distribution of GAGs and sustained release of any sequestered growth factors through the 
duration of the culture to better promote chondrogenesis, as has been explored previously 
with  degradable gelatin and PLGA MPs in MSC pellets [141, 143].  Alternatively, the 
use of smaller CSMA MPs in the spheroids may also promote more uniform dispersal 
throughout the aggregate ECM as seen in the incorporation of PLGA MPs (1-11µm 
diameter) in embryonic stem cell aggregates [160] or the addition of RGD sequences in 
CSMA to enable direct cell attachment to MPs.  Together, such a spheroid system would 
more closely mimic the native ECM by achieving a more homogeneous distribution of 
















In these studies, we have demonstrated that the incorporation of CSMA MPs in 
hMSC spheroids did not adversely affect TGF-β1-mediated chondrogenesis and that MPs 
promote earlier gene expression of chondrogenic markers compared to spheroids without 
MPs. In addition, the clustering of CSMA MPs resulted in unique cellular and ECM 
alignment in the MSC spheroids that may provide a means to spontaneously form areas 
of high alignment within microtissues. As GAGs are found in a wide variety of tissue 
types, such results indicate that this culture system can serve as a novel platform both to 
further examine the effects of GAGs and growth factors on MSC phenotype, as well as 
potentially direct differentiation in a more spatially controlled manner that better mimics 















CSMA MP Incorporation Efficiency Analysis 
Materials and Methods  
Following the aforementioned MSC spheroid formation technique, CSMA 
microparticles were incorporated in the MSC spheroids at 1:3, 1:1, and 3:1 MP:cell 
number ratios. Samples were collected on day 1 after formation for Safranin-O staining 
using the same histological procedure in this study. After the number of spheroids per 
sample was determined, the MSC spheroids were dissociated by incubating in 0.25% 
trypsin for 1 hour at 37°C (5% CO2 and 20% O2). To isolate the MPs from the dissociated 
MSCs, 5% sodium dodecyl sulfate (SDS) was then added to the cell-MP suspension for 5 
minutes. The number of MPs was determined on a hemocytometer and divided by the 
number of MSCs based on the previous spheroid count to determine the experimental 
MP:cell ratio.  
Results 
Difference in the amount of MPs incorporated in the MSC spheroids can be 
observed compared to the no MP control (Fig. A1A-D). The incorporation efficiency of 
the CSMA MPs was quantitatively assessed for a range of MP:cell number ratio (1:3, 1:1, 
and 3:1), which showed that nearly all of the MPs loaded become incorporated within the 





Figure A1. Efficiency of CSMA microparticles incorporation in MSC spheroids. Increasing amounts of 
CSMA microparticles (red) incorporated in the MSC spheroids was shown by Safranin-O staining (A-D). 
The theoretical loaded MP:cell ratios corresponded closely to the ratio evaluated by spheroid dissociation 

















CSMA MP Clustering Effect 
Materials and Methods  
MSC spheroid formation and MP incorporation was done using the same protocol 
detailed in this study. CSMA MPs were added at to the MSC cell suspension at a 3:1 
MP:cell ratio and the polystyrene MPs were added at a 6:1 ratio to achieve comparable 
numbers of incorporated MPs in the spheroids due to a lower incorporation efficiency. 
The spheroids were cultured in the same chondrogenic conditions under hypoxia in 
alginate layers and collected at day 1 and 7 for processing using the same histological 
procedure described previously without the application of any stains. The spheroids were 
then imaged using a phase contrast microscope.   
Results  
 At day 1, a random distribution of both CSMA and polystyrene MPs was 
observed in the MSC spheroids (Fig. A2A, C). However, the CSMA MPs became 
organized into a cluster in the center of the spheroid by day 7 with distinct organization 
around the MP core (Fig. A2B). In contrast, the polystyrene MPs remained distributed 
across the spheroid ECM without any pronounced rearrangement, indicating possible 




Figure A2. CSMA microparticles cluster by day 7 in hMSC spheroids. CSMA (A) and polystyrene (C) 
microparticles were distributed throughout the spheroids on day 1 (arrows). However, the CSMA 
microparticles aggregated after a week of culture (B), whereas the polystyrene microparticles remained 















Negative Lineage Marker Gene Expression 
Materials and Methods 
Quantitative RT-PCR was performed using the SYBR Green Master Mix using 
the same procedure for the gene expression analysis in this study. The raw fluorescence 
data was also processed in LinReg PCR software and normalized by Box-Cox 
transformation prior to statistical analysis with ANOVA. Fold regulation relative to the 
untreated Day 1 control was also determined for each sample with 18S ribosomal protein 
and β-actin as endogenous housekeeping controls.  
Results  
Less RUNX2 expression was detected in +MP +TGF-β spheroids at day 21 
compared to +TGF-β spheroids (Fig. A3A) and both +TGF-β and +MP +TGF-β 
spheroids demonstrated reduced MyoD expression compared to the untreated group for 
all time points (Fig. A3B).  
 
 
Figure A3. Gene expression of negative lineage markers in MSC spheroids. RUNX2 expression was 
sustained from day 7 to 21 in all groups (A) and MyoD expression was decreased over 21 days in all 
groups (B). n=3, * indicates significantly different from same treatment at Day 1 (p<0.05).  
#
 indicates 
significantly different from the untreated at the same time point (p<0.05). 
+
 indicates significantly different 




Microabrasion Cartilage Defect Model 
Materials and Methods 
The Gold Series MegaPeel microdermabrasion machine (DermaMed USA, Lenni, 
PA) with the gold handpiece assembly from the Prausnitz laboratory was used for 
microabrasion of articular cartilage. By sealing the opening on the plastic tip of the 
handpiece, vacuum forms and drives the flow of the silica crystals from the machine to 
the target surface. During abrasion, the tissue debris and crystal circulate in the plastic tip 
and are directed back into a closed waste container. The crystal flow rates have been 





and the suction pressure from 30 kPa to −60 kPa [162]. The flow rate was adjusted to the 
maximum setting (“9” on the dial), which corresponded to roughly 10
5
 particles/s, for 
cartilage microabrasion [162]. Microabrasion masks were made from stainless steel 
sheets (75μm thickness, Trinity Brand Industries, Countryside, IL) by Vladimir 
Zarnitsyn, PhD from the Prausnitz laboratory. Holes (120, 250, 275µm diameters) were 
patterned on the masks using AutoCAD software (Autodesk, San Rafael, CA) and an 
infrared laser (Resonetics Maestro, Nashua, NH).  
Femur and tibia were harvested from calf legs (Research 87, Marlborough, MA) 
while intact hind legs were retrieved from practice rats for microabrasion on the 
articulating joint surface. To abrade the bovine cartilage, the handpiece was positioned so 
that the tip opening was flush against a rubber seal that sits above the cartilage surface as 
seen in Fig. A4. The length of the microabrasion ranged from 3, 6 to 12 minutes. 
Abrasion with and without the stainless steel masks, which were inserted between the 
rubber seal and cartilage surface as shown, were also tested. The abraded bovine cartilage 
52 
 
was removed from the respective femur or tibia with a scalpel. Another piece of cartilage 
was removed from the vicinity as unabraded controls. The samples were infiltrated with 
OCT-sucrose solutions as described previously before embedding and cryosectioning at 







Figure A4. Cartilage microabrasion schematic. The microabrasion handpiece was used in conjunction with 
a rubber seal and stainless steel mask to abrade cartilage (A). The handpiece was placed on top of the seal 
above the cartilage. When the mask was in use, it was inserted between the rubber seal and the cartilage 
surface (B). 
 
The medial condyles of harvested rat femurs were similarly abraded without the 
mask and the lateral condyles from the same joint served as unabraded controls. In intact 
rat legs, the femoral groove required surgical isolation prior to microabrasion. An 
incision was first made along the length of the medial side of the patellar tendon (Fig. 
A5A). The knee was flexed and the patellar tendon was dislocated laterally to expose the 
femoral groove for microabrasion as seen (Fig. A5B). Similar to the microabrasion of 
bovine cartilage, the handpiece was immobilized over the target tissue on top of the 
rubber seal with or without the stainless steel mask (Fig. A5C). After the abrasion, the 
femur was harvested and incubated in 1% protease inhibitor cocktail (CalBiochem, San 
Diego, CA) and ionic contrast agent Hexabrix 320 (Mallinckrodt, Hazelwood, MO) 
solution for 1 hour. The abraded femurs were imaged in a 12mm scanning tube with µCT 
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40 (Scanco Medical, Bassersdorf, Switzerland) at 45kVp, 177µA, 200ms integration time 
and a voxel size of 12µm [163]. Using the equilibrium partitioning of an ionic contrast 
agent (EPIC) technique [163], the cartilage morphology and proteoglycan composition of 
the abraded joints were determined.  
Figure A5. Isolation of rat femoral groove for microabrasion. An incision was made along the medial 
length of the patellar tendon (black double-ended arrows) (A) in order for the femoral groove (black box) to 
be exposed in the flexed joint (B). The handpiece was then placed over the exposed cartilage for 
microabrasion (C). * indicates the distal end of the joint.  
 
Results 
The Gold Series MegaPeel microdermabrasion system has been previously 
characterized for controlled abrasion of porcine skin [162]. The process was adopted for 
the development of a cartilage defect model with some modifications. Due to the 
curvature of the cartilage surface, a rubber seal was used to better maintain the vacuum 
between the handpiece and the target tissue. The stainless steel masks were added with 
the goal of creating a pattern of focal defects in the cartilage. The microabrasion process 
was initially tested on bovine cartilage and later refined for intact rat joints.  
The superficial zone of bovine cartilage was removed after 3, 6, and 12 minutes of 
microabrasion without the mask compared to the unabraded controls (Fig. A6A-F). 
However, the amount of tissue abraded from the surface did not appear to increase with 
the length of microabrasion time. Bovine cartilage was also abraded for 12 minutes with 
54 
 
the stainless steel mask of 125μm diameter holes. However, large variations in the size 
and morphology of surface defects created by the microabrasion process were observed 
between samples (Fig. A7D-F). 
 
Figure A6. Surface fibrillation in bovine cartilage after 3, 6 or 12 minutes of microabrasion. Unabraded 
cartilages exhibited an intact superficial zone (A-C) while abraded samples showed similar loss of tissue at 
the surface (D-F) independent of microabrasion time. Scale bar = 50μm. 
 
 
Figure A7. Variable surface fibrillation in bovine cartilage after 12 minutes of abrasion with mask (125μm 
diameter holes). The superficial layer of unabraded cartilage remained intact (A-C). Some surface 
disruption was seen in sample 1 (D) while sample 2 exhibited a pattern of lesion (E) and sample 3 showed a 
focal defect (F). Scale bar = 50μm. 
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Some surface roughness and flattening was observed in all of the abraded rat 
condyles with μCT (Fig. A8A-D, arrows). The cartilage thickness quantified by EPIC 
was lower for the abraded condyle compared to the unabraded control for all abrasion 
time (Fig A8E). Higher attenuation values were generally observed in the abraded 




Figure A8. Microabrasion of rat condyles visualized and quantified by μCT. Disruption to the articular 
cartilage surface were observed for all abrasion times (B- D) compared to the unabraded control (A). 
Quantitative analysis showed reduced cartilage thickness after abrasion along with increased attenuation 
values (E). Scale bar = 1mm, n=1. 
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Similarly, surface roughness could be seen in the rat femoral grooves that were abraded 
for 6 and 9 minutes. The area of abrasion extended across the entire width of the femoral 
groove and in patellar surface in the 6 min sample (Fig. A9B, arrow), whereas the pattern 
of abrasion mainly localized along the grooves in the 9 min sample (Fig. A9C, arrows).  
The difference in the abrasion pattern may be partially contributed by the difficulty in 
positioning the handpiece and seal tightly against the curvature of the groove. Because 
the thickness of rat cartilage is much lower than that of bovine cartilage, microabrasion 
for 12 minutes resulted in the complete erosion of the tissue (Fig. A9D, arrow). 
Reduction of abrasion time and the use of stainless steel mask still need to be further 
investigated in the rat cartilage model.   
 
 
Figure A9. Microabrasion of the rat femoral groove. Abrasion for 6 and 9 minutes induced visible surface 
roughness (B, C). However, 12 minutes of abrasion caused the complete removal of cartilage from the 




Microdrilling Cartilage Defect Model 
Materials and Methods  
Cartilage Explant Harvest 
Bovine femur was similarly harvested from fresh calf legs as previously 
described. David Reece from the Guldberg Lab contributed greatly to the development of 
the microdrilling procedure. Prior to microdrilling, the bovine femur was immobilized on 
the stereotaxic instrument (David Kopf Instruments, Tujunga, CA) as seen in Fig. A10. A 
dissecting scope was used to visualize the tip of the 0.25mm diameter microdrill bit 
(Midwest Circuit Technology, Aurora, OH) and to position it perpendicularly and flush 
against the condyle cartilage surface that has been pre-marked in 6mm diameter circles. 
A pattern of ten microdefects 100µm deep and 1mm apart was achieved within the 6mm 
diameter circles. The cartilage was then excised from the condyle by cutting along the 
pre-marked boundaries with a scalpel to obtain a relatively circular explant with a few 
millimeters in thickness. For histology, the cartilage explants was first fixed in 10% 
formalin. The surface of the explants was stained with Alcian Blue in order to visualize 




Figure A10. Bovine cartilage microdrilling setup. The bovine femur was fixed to a styrofoam block and 
immobilized on the stage of the stereotaxic instrument. The stereoscope was then positioned over the 
articular cartilage to visualize the drill bit during the microdrilling procedure. 
 
CS-NHS Conjugation 
The protocol of CS-NHS conjugation was developed by Torri Rinker. One liter of 
95% ethanol was first chilled at -20°C. A 10% (w/v) chondroitin sulfate-C (463.369 
g/mol), a 25% (w/v) N-hydroxysuccinimide (NHS) (115.087 g/mol) and a 67% (w/v) N-
(3-dimethylamino propyl)-N’-ethyl carbodiimide hydrochloride (EDC) (191.70 g/mol) 
solution was prepared with incomplete PBS (no Ca and Na ions). The CS, EDC, and 
NHS solutions were then combined in a 7:1.5:1.5 ratio (v/v) and thoroughly mixed on a 
stir plate. Following a 10 minute incubation in the 37°C oven, the solution was 
transferred to a beaker so that the total volume forms a thin layer that just covers the 
bottom. Immediately after the beaker was flash frozen in liquid nitrogen, an excess of 
previously chilled 95% ethanol was added. The mixture was allowed to stir for 30 
minutes for the CS-NHS to precipitate. While waiting, the Buchnur funnel was prepared 
with two layers of filter paper (Whatman) and placed on top of the Bucher flask with a 
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rubber seal, which was connected to the vacuum. The CS-NHS product was removed 
from the beaker, transferred to the filter paper and tapped dry with a spatula prior to 
vacuum drying. 
Individual spheroid delivery    
Microdrilled bovine cartilage was removed from the tibia with a scalpel adhered 
to the bottom of a 35mm x 10mm Petri dish with an acrylate glue for subsequent 
procedures. The cartilage explant was sterilized by incubation in 95% ethyl alcohol for 1 
hour, followed by two 30 min washes in complete PBS.  
A 10% (w/v) 8-arm PEG amine solution and a 10% (w/v) CS-NHS solution were 
prepared in PBS and sterile filtered. The two solutions were then combined in a 1:1 ratio 
immediately before usage for spheroid placement in the cartilage defects.  
Human MSC spheroids were formed by a forced aggregation method using 
agarose microwell inserts that were patterned from Aggrewells. A single cell MSC 
suspension (4.2 million cells) was added to the agarose microwell inserts and centrifuged 
(200 rcf, accel 0, decal 3) to aggregate cells within the microwells. After 24 hours, the 
fully formed 700-cell MSC spheroids were rinsed out of the microwells.  Under a 
dissecting scope in a sterilely vented horizontal flow hood, individual hMSC spheroids 
were picked up with a 0.125mm diameter tungsten needle (Fine Science Tools, Foster 
City, CA) and placed into a microdefect in the cartilage explant. Immediately following 
placement, a drop of CS-NHS glue was laid over the MSC spheroid in the microdefect 
using the blunt end of the tungsten needle. The process was repeated until all defects have 
been filled. With a wide-bore pipette, 3mL of MSC growth media was then added to the 
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Petri dish to completely submerge the cartilage explant. The media was subsequently 
changed every other day for up to 7 days.  
After 7 days in culture, the cartilage explant was incubated in the Live/Dead 
solution for 1 hour and washed in complete PBS for an additional hour. Fluorescence 
imaging of the explants was performed on the confocal microscope (Zeiss LSM 700, 
Oberkochen, Germany). For histology, the day 7 cartilage explant was fixed in 10% 
formalin for 1 hour by incubation. The explant was then washed in complete PBS for 
another hour before embedding in Histogel. A thin layer of histogel was first added to the 
bottom of a 10x10x5mm cryomold before placement of the cartilage explant and 
additional volume of histogel to ensure that the explant remains suspended while the 
histogel solidifies overnight. The histogel-embedded explant was then infiltrated in 
sucrose:OCT solutions of varying ratios using the standard protocol overnight under 
vacuum. The explant was transferred from well to well during the infiltration carefully so 
that the histogel remained intact. The infiltrated sample was then embedded in OCT for 
cryosectioning at 10µm thickness and stained with H&E. To visualize the spheroids in 
the explant, the aggregates were dipped in a Fast Green stain using the tungsten needle 
and rinsed off with PBS before placement in individual defects.  
Results 
A precise pattern of defects in the cartilage explant was achieved with 
microdrilling (Fig. A11A, arrows). The stereotaxic instrument allowed accurate control 
over the depth of each defect and the spacing between defects. Individual MSC spheroids 
could be placed in each defect with a coating of the CS-NHS glue for cartilage explant 
culture (Fig. A11B). After 7 days, histology and confocal microscopy confirmed the 
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presence of spheroids in the defects (Fig. A11C), which indicates that the shear forces 
from the flow of the media did not displace the spheroids. In addition, the MSC spheroids 
retained viability after one week in the cartilage explant culture as shown by the 
Live/Dead staining (Fig. A11D). The results suggest that the CS-NHS glue did not 
adversely affect diffusional transport of nutrients or other biomolecules to and from the 
MSC spheroids within the cartilage defects. Long term culture of spheroids in the bovine 
cartilage explants and more thorough characterization of the MSC phenotype after culture 
should be investigated in future studies.  
 
 
Figure A11.  Visualization of MSC spheroid in cartilage microdefects. Alcian Blue staining of bovine 
cartilage demonstrated a distinct pattern of microdefects (A).  MSC spheroids stained with Fast Green were 
individually placed in the cartilage microdefects (B). MSC spheroids remain in cartilage microdefects after 
7 day in culture as shown by H&E staining (C). After 7 days in culture, MSC spheroids in cartilage 





CSMA Microparticle Preparation 
CSMA Microparticle Formation 
1) Remove chondroitin sulfate methacrylate (CSMA) from -20°C and allow to warm 
up to room temperature for 30 minutes on ice 
2) Place 60 mL of corn oil in the 4°C refrigerator 
3) Make APS solution in 1.5 mL tube: 34.2 mg APS in 500 µL PBS 
4) Make TEMED solution in 1.5 mL tube: 22.5 µL in 500 µL PBS 
5) Make sure everything is on ice to prevent crosslinking 
6) Weigh out 55.6 mg CSMA in a scintillation vial and add 440uL of PBS 
7) Homogenize corn oil at 3900 rpm for 5 minutes 
8) Add 30 uL of APS and 30 uL of TEMED to the CSMA solution, mix, and add 
solution dropwise to corn oil (** Do NOT mix APS and TEMED together before 
adding to the CSMA solution**) 
9) Homogenize emulsion for 5 minutes 
10) Place corn oil mixture on a hot plate (set to 100°C) with the largest stir bar that 
will fit in the container (to keep particles moving so as not to crosslink with one 
another) and a thermometer (to monitor temperature - let it go up to 50-60°C).  
11) Allow mixture to crosslink for 30 minutes with nitrogen purging 
12) Set centrifuge temperature to 4°C 
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13) Separate mixture into two 50 mL conical tubes and centrifuge at a minimum of 
1500 rpm for 5 minutes at 4°C 
14) Remove oil from microparticles and resuspend pellet in ddH2O and transfer to 1.5 
mL tube 
15) Wash 3 times to remove oil 
16) Store at 4°C for immediate use 
17) For long term storage, remove all ddH2O and place in freezer for 10-20 min until 
frozen 
18) Cover 1.5mL tubes with punctured aluminum foil and place in lyophilizer tube 
19) Lyophilize until microparticles are dry (minimum overnight) 
20) Remove lyophilized microparticles and store at -20°C  
CSMA Microparticle Sterilization (before lyophilization) 
1) Prior to lyophilization (step 17), add 1mL of 90% ethanol to the microparticles for 
1 hour at 4°C on the rotary 
2) Wash microparticles 3 times to remove ethanol 
3) Remove all ethanol and place in freezer for 10-20 min until frozen 
4) Cover 1.5mL tubes with punctured aluminum foil and place in lyophilizer tube 
5) Lyophilize until microparticles are dry (minimum overnight) 
6) Remove lyophilized sterile microparticles and store at -20°C  
CSMA Microparticle Growth Factor Loading (after lyophilization) 
1) Add growth factor dropwise to lyophilized microparticles at desired concentration 
(exp: 100ng TGF-β1 per mg of CSMA microparticles)  
2) Incubate microparticles in growth factor solution overnight at 4°C on rotary 
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3) Remove supernatant and re-suspend in appropriate buffer (exp: media, PBS) for 
cell culture or release study 
CSMA Microparticle Growth Factor Release  
1) Loading concentration (from cell study): 100ng TGF-β1/1mg CSMA MP 
2) 2mg CSMA MP/tube  
3) 200ng TGF-β1/tube  
4) Loading control: no MP + 200ng TGF-β1/tube (n=3) 
a. A no MP control has been previously done for growth factor loading 
b. Will be used to determine amounts of TGF-β not available for loading due 
to adsorption to the tube 
5) Small volume (~50µL) loading 
6) 18 hour overnight loading at 4°C 
7) Time points: 3 hrs, 1, 3, 6, 9, 12, 15 days 
a. 3 hrs: burst release – unsequestered growth factors 
8) Temperature: 37°C 
9) Remove PBS at each time point and replenish with same volume (1mL) 









MSC Spheroid Formation 
Materials  
-3% w/v agarose solution  
-glass jar 
-AggreWell wafers  
-70%EtOh 
-Petri dish (100mm) 
-tweezers (PDMS) or spatulas (agarose) 
-MSCs and media  
-6-well or 24-well plates 
-Pipettor/pipettes 
-Wide-bore pipette tips (1000uL) 
-15mL centrifuge tubes 







-Plate holders for centrifuge  
-LabRoller rotator (or any mini 
centrifuge tube rotisserie rotator)  
-Rotary shaker  
-Incubator  
Methods 
Making AggreWell Inserts with agarose:  
1) Make a 3% (w/v) agarose solution, store in a glass jar at room temperature.  
2) Autoclave using liquid cycle. 
3) Spray AggreWell wafer with ethanol and wipe down to get off any particulates. 
Place in cell culture hoods under UV for at least 10 minutes.  
4) If agarose solution is solid, heat up in microwave. 
a. Unscrew cap to loosen 
b. Heat in 1-2minute intervals. Shake in between heating.  
c. Note: Glass jar will get HOT, wear autoclave gloves.  
5) Let jar cool and bring into hood.  
6) Use pipette to transfer 3mL to each wafer insert. Use pipette tip to spread and 
cover whole area of insert.  
7) Also use pipette to remove any bubbles or excess so that insert is not overfilled. 
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8) Let agarose solidify, will take 3-4 minutes.  
9) Use flat and thin spatula to cut edge and scope out mold.  
10) Transfer to 6-well plate. Use back of spatula (if it is rounded or flat) to push mold 
to the bottom of the mold.  
11) If storing agarose molds overnight, add 2mL PBS to well with molds and store at 
room temperature. 
Making Spheroids through UHTP/AggreWell method: 
1) Prep cells for spheroids (trypsin, resuspension, counting).  
2) Add media to the large (6-well) inserts or small (24-well) inserts so that the total 
volume after adding cells will be 3 mL for the large inserts or 1 mL for the small 
inserts. 
3) Spin at 3000g for 5 minutes. (Accel/Decel: 9) 
4) Add appropriate volume of cell solution and let settle for 5 minutes. 
a. For 1000-cell spheroid, add 6 x 106 cells to large (6-well) inserts (~6000 
spheroids)  
b. Make 500-cell MSC spheroids for anti-inflammatory assay  
c. If adding particles, add the particles to cell solution and mix, then transfer 
cells/microparticle solution to wells. Microparticle:cell ratio depends on 
microparticle composition and spheroid size.  
5) Spin at 200 g for 5 minutes. (Acceleration: 0, Deceleration: 3) 
6) Place plate in incubator where it will not be disturbed (try not to bump!) for 1 day.  
7) After 16-18 hours, use a wide-bore pipette tip to “pop out” the spheroids by 
gently pipetting up and down with media gently all over the insert, then transfer 
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volume to a 15mL centrifuge tube. Add fresh media into well plates and repeat 
pipetting “pop out” as necessary until all EBs/spheroids are removed (2-3x). 
Minimize bubble formation.  
8) Check inserts under microscope for any leftover spheroids.  
a. For PDMS inserts, do not let cells incubate for longer than 18hrs- 
spheroids will start to adhere to PDMS, making it difficult to “pop out”.  
9) Let the spheroids settle (~5min) in centrifuge tube, then remove all but the bottom 
1 mL of volume. Do not aspirate, just use pipettor to take off supernatant media.  
a. If settling takes a long time, place centrifuge tube in incubator and wait 
~10 minutes.  
10) Add 9 mL of media to centrifuge tube and transfer to non-tissue culture treated 
100mm petri dishes. 
a. Large inserts are typically split into 3 plates, while small inserts are 
enough for one plate 
11) To change media, transfer spheroid suspension to 15mL centrifuge tube (make 
sure no spheroids left on plate). Let spheroids settle in tube, and remove 9mL of 









MSC Spheroid Alginate Encapsulation 
Background 
- Alginate encapsulation of MSC spheroids minimizes agglomeration and loss of 
aggregates over extended culture periods (up to 21+ days) 
- Protocol below is written specifically for MSC spheroids, but can be applied to 
other cell types 
Materials 
- 1.5% sodium alginate in ddH20 (sterile filtered) 
- 100mM calcium chloride (sterile filtered) 
- 55mM sodium citrate (sterile filtered) 
- 10U/mL alginate lyase (non-sterile) 
- #4 Whatman filter paper 125mm (trimmed to 75mm diameter, autoclaved) 
- Forceps (autoclaved) 
- Low attachment plates 
Protocols 
Alginate Encapsulation (after formation of spheroids in insert): 
1. Pellet MSC spheroids and aspirate media supernatant 
2. Wash spheroids with complete PBS 
3. Add alginate to the pellet and mix for a uniform solution 
- ~5mL of alginate can be used to form one gel depending on desirable 
thickness 
4. Prepare a petri dish of CaCl2 solution 
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5. Using a pair of forceps, fully soak the filter paper in the CaCl2  
6. Carefully place the filter paper over the alginate 
- The filter paper will draw the alginate across the entire plate 
7. Add 2mL of CaCl2 on top of the filter paper 
8. Allow alginate to crosslink for 10 minutes 
9. Remove the filter paper with the forceps 
10. Add 9mL of media to the plate 
Alginate Dissociation (for collecting samples): 
1. Aspirate all of the media 
2. Wash alginate gel with incomplete PBS (at least two times) until it is no longer 
pink 
3. Add 10mL of sodium citrate per plate 
4. Incubate on the rotary at 37C for 30 minutes 
5. Transfer the sodium citrate-spheroid mixtures to conical tubes 
6. Pipette up and down to ensure all of the alginate has dissociated 
7. Add more sodium citrate if necessary to dissociate any alginate remnants 
8. Allow spheroids to pellet and aspirate the sodium citrate 
9. Wash spheroids with complete PBS (at least two times) 
10. Add 300µL of alginate lyase to the pellet 
11. Incubate at 37C for 20 minutes 







Fixative (Acetone, formalin, formaldehyde)  
Block serum (1.5% in PBS) 
1°Ab (in 1.5% serum) 
2°Ab (in 1.5% serum) 
Nuclear counterstain (Hoechst 1:100 in ddH2O) 




Order Info Isoform Dilution Deglycosylate Blocking 




IgG 1:60 N Image-iT 
Collagen II Abcam (ab3092) IgG 1:20 N Image-iT 








IgM 1:50 N Serum 
 
Deglycosylation 
Activation buffer (50mM Tris, 60mM sodium acetate, 0.02% BSA, pH 8.0) 
Activate chondroitinase ABC in the activation buffer 
Dilute 1 U/mL chondroitinase 3:4 with 4X activating buffer  




Antigen Retrieval  
TE-CaCl2 buffer (50mM Tris Base, 1mM EDTA, 5mM CaCl2, 0.5% Triton X-100, pH 
8.0)  
- Tris Base (6.10g) 
- EDTA (0.37g) 
- CaCl2 (0.56g) 
- Triton X-100 (5mL) 
- Distilled Water (1000mL) 
- Store at room temperature 
 
Proteinase K stock solution (20X, 400µg/mL) 
- Proteinase K (30 U/mg) (8mg) 
- TE-CaCl2 buffer (10mL) 
- Glycerol (10mL) 
- Add proteinase K to TE-CaCl2 
buffer until dissolved 
- Add glycerol and mix well 
- Aliquot and store at -20°C for 2-
3 years 
 
Proteinase K working solution (1X, 20µg/mL) 
- Proteinase K stock solution (1mL) 
- TE-CaCl2 buffer (19mL) 
- Mix well 
- Stable at 4°C for 6 months 
Frozen Sections 
1) Incubate in water for 5 min to remove OCT 
2) For unfixed sections:  
a. Fix in acetone (NBF, paraformaldehyde, methanol) for 5 min 
b. Wash 2X in PBS for 5 min 
3) For fixed sections: 
a. Incubate in Proteinase K solution for 10 min at 37°C 
b. Wash 2X in PBS for 5 min 
4) For Aggrecan and Collagen X antibodies: 
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a. Deglycosylate in 0.75U/mL chondroitinase ABC (30µL) for 1.5 hours at 
37°C 
b. Wash 2X in PBS for 5 min 
5) Block with 1.5% serum from species of secondary Ab in PBS for 1 hour 
6) Incubate in 1°Ab (in 1.5% serum) at RT for 1 hour or 4°C overnight 
7) Wash 3X in PBS for 5min 
8) Incubate in 2°Ab (1:200) (in 1.5% serum) at RT for 1 hour  
9) Wash 3X in PBS for 5 min 
10) Incubate in nuclear counterstain (Hoechst) for 5 min 
11) Wash 2X in PBS for 5min 
12) Wash in water for 5min 















Step Solution Time Temp Concen Volume 
1 Water 5 min RT   
2 Fixative 20 min RT   
3 PBS 5 min RT   
4 PBS 5 min RT   
5 Proteinase K 10min 37°C  
100µL x 
______=__________ µL 
6 PBS 5 min RT   
7 PBS 5 min RT   
8 Chondroitinase ABC 1.5 hour 37°C  
30µL x 
______=__________ µL 
9 PBS 5 min RT   
10 PBS 5 min RT   
11 Block (serum or Image-iT) 30 min RT   
* PBS (Image-iT) 5 min    
* PBS (Image-iT) 5 min    
12 1°Antibody/Isotype Overnight 4°C 1:20 
100µL x 
______=__________ µL 
13 PBS 5 min RT   
14 PBS 5 min RT   
15 PBS 5 min RT   
16 2°Antibody 30 min RT 1:200 
100µL x 
______=__________ µL 
17 PBS 5 min RT   
18 PBS 5 min RT   
19 PBS 5 min RT   
20 Nuclear Stain 5 min RT 1:100 
100µL x 
______=__________µL 
21 PBS 5 min RT   
22 PBS 5 min RT   
23 Water 5 min RT   









CS-NHS Conjugation (adapted from Torri Rinker) 
Reagents 
- Chondrotin Sulfate C (CSC): 463.369 g/mol 
- N-hydroxysuccinimide (NHS): 115.087 g/mol 
- N-(3-dimethylamino propyl)-N’-ethyl carbodiimide hydrochloride (EDC): 191.70 
g/mol 
- PBS (without Ca and Na) 
Supplies
- aluminum foil, needle 
- vortex 
- Buchner flask 
- Buchnur funnel 
- 2 filter papers 
- Tubing 
- high vacuum 
- ethanol (EtOH) 
- scintillation vial 
CS-NHS Conjugation Procedure 
1) Store 95% EtOH in -20°C 
2) Make the following solutions in PBS and mix well:  
a. 10% (w/v) CS-C 
b. 25% (w/v) NHS 
c. 67% (w/v)  EDC 
3) Combine CS, EDC, and NHS in a 7:1.5:1.5 ratio (v/v) 
a. Volume CS: 
b. Volume NHS: 
c. Volume EDC: 
4) Mix on stir plate in hood 
5) Place in the 37°C oven for 10 minutes. 




Flash freeze in liquid nitrogen. 
7) Immediately add an excess of -20°C 95% EtOH to the beaker (______  mL) 
8) Wait 30 minutes for CS-NHS to precipitate while stirring. 
9) Place two filter papers in the Buchnur funnel and place the funnel on top of the 
Bucher flask with a rubber seal. Hook flask to vacuum. 
10) Transfer the product from the beaker to the filter paper. Rinse the beaker with 
EtOH (______ mL). Keep the liquid portion for assaying purposes.  
11) Use a spatula to split up the product and get it as dry as possible. Then, vacuum 
dry.   
CS-NHS Glue Procedure 
1) Dissolve CS-NHS in PBS (10% w/v) and the 8 arm PEG in PBS (10% w/v) first 
2) For a total of 100uL, weigh out10mg of CS-NHS and add it to 100uL of PBS 
3) Make about 200uL extra for sterile filtering.  
4) Combine the CS-NHS and PEG in a 1:1 ratio.  
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